VolitionRx Publishes Breakthrough Liquid Biopsy Technology in Peer-Reviewed Study — VolitionRx Limited (Volition)

Event summary

VolitionRx published its first peer-reviewed paper on Capture-Seq™, a novel liquid biopsy technology that isolates >99% pure circulating tumor-derived DNA (ctDNA).
The study demonstrated no false positives and detected 49/49 early-stage cancers in initial cohorts.
Capture-Seq™ targets a $36 billion total addressable market (TAM) for multi-cancer early detection (MCED) and minimal residual disease (MRD).
VolitionRx is in active discussions with global diagnostic leaders to accelerate commercialization.

The big picture

VolitionRx's Capture-Seq™ technology addresses a critical limitation in liquid biopsy methods by isolating pure ctDNA, potentially revolutionizing cancer detection. The $36 billion TAM underscores the strategic significance of this breakthrough in an industry increasingly focused on early cancer diagnosis and monitoring. Success hinges on partnerships with diagnostic leaders and further validation in larger patient cohorts.

What we're watching

Commercialization Pace: Whether VolitionRx can secure licensing agreements with diagnostic leaders to accelerate Capture-Seq™ development.
Validation Scaling: The pace at which larger cohorts validate the technology's early-stage cancer detection capabilities.
Market Adoption: How Capture-Seq™ integrates with existing multi-cancer early detection (MCED) and minimal residual disease (MRD) monitoring frameworks.